Kalp Yetersizliği Hastasına Yaklaşım
Synopsis
Heart failure (HF) is a clinical syndrome with high mortality characterized by symptoms such as shortness of breath, fatigue, and edema, resulting from cardiac abnormalities. Coronary artery disease, hypertension, and diabetes are the primary underlying etiologies. HF is classified by ejection fraction into reduced (HFrEF), mid-range (HFmrEF), and preserved (HFpEF), as well as categorized by functional capacity via NYHA (Classes I-IV) and progression stages via ACC/AHA (Stages A-D). History and physical examination are essential for diagnosis, with orthopnea, paroxysmal nocturnal dyspnea, and bendopnea being key symptoms. Initial diagnostic tools include serum natriuretic peptides (BNP, NT-proBNP), ECG, and echocardiography. Acute HF management categorizes patients into clinical profiles based on congestion and hypoperfusion status (warm-dry, warm-wet, cold-dry, cold-wet). Immediate assessment checks for cardiogenic shock, requiring inotropic/vasopressor agents like dobutamine or norepinephrine, or mechanical circulatory support when present. Non-invasive positive pressure ventilation (CPAP/BiPAP) is prioritized for respiratory failure, while IV diuretics and vasodilators relieve congestion. Following stabilization, long-term pharmacotherapy including ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists is initiated.
References
Ponikowski P, Voors AA, Anker SD, et all. 2016 ESC Guidelines for the Diagnosis andTreatment of Acute and Chronic Heart Failure. Rev Espanola Cardiol Engl Ed. 2016;69(12):1167.
Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008 Oct;10(10):933-89. doi: 10.1016/j.ejheart.2008.08.005. Epub 2008 Sep 16. Erratum in: Eur J Heart Fail. 2009 Jan;11(1):110. Erratum in: Eur J Heart Fail. 2010 Apr;12(4):416. Dosage error in article text.
Değertekin M, Erol C, Ergene O, et al. Heart failure prevalence and predictors in Turkey: HAPPY study. Arch Turk Soc Cardiol 2012;40:298-308
Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90
Bonow: Braunwald's Heart Disease - A Textbook of Cardiovascular Medicine, 9th ed.2012
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2012;14(8):803-69.
Yancy CW, Jessup M, Bozkurt B,et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239.
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256
Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011;124:2865–2873.
Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: which features are any use? QJM 1997;90:335–339.
Thibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez-Martinez M, Mishkin JD, Patel PC, Mammen PPA, Markham DW, Levine BD, Drazner MH. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail 2014;2:24–31.
Maisel A, Mueller C, Adams K,et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824–839.
Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT- proBNP: Mechanisms and diagnostic implications for heart failure. Int J Cardiol 2014;176:611–617.
Adalet K. KLİNİK KARDİYOLOJİ Tanı ve Tedavi.2019. 2 st ed İstanbul Tıp Kitapevleri